In the Paola/ENGOT-ov25 phase III trial, the 5-year overall survival (OS) rates in patients with BRCA1/2 mutations and/or with HRD-positive newly diagnosed advanced ovarian cancer were 65% and 55%, respectively, with olaparib and bevacizumab as a maintenance treatment [7]. This evidence concerns the gene BRCA1 and ovarian cancer.